Investors who lost money on Alto Neuroscience, Inc.(ANRO) should contact The Gross Law Firm about pending Class Action - ANRO

Core Points - The Gross Law Firm has issued a notice to shareholders of Alto Neuroscience, Inc. regarding a class action lawsuit for those who purchased shares during a specified period [1][3] - The lawsuit alleges that Alto Neuroscience made materially false and misleading statements about its product pipeline, specifically the effectiveness of ALTO-100 in treating major depressive disorder [2] - Shareholders are encouraged to register for the class action by the deadline of September 19, 2025, to potentially be appointed as lead plaintiff [3] Summary by Sections Class Action Details - The class action is on behalf of all persons and entities that purchased Alto common stock during the initial public offering on February 2, 2024, and/or between February 2, 2024, and October 22, 2024 [1] - Registration for the class action is free, and participants will receive updates throughout the case lifecycle [3] Allegations Against Alto Neuroscience - The complaint claims that the effectiveness of ALTO-100 was overstated, leading to inflated clinical, regulatory, and commercial prospects [2] - As a result of these misleading statements, Alto's business and financial prospects were also overstated [2] Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [4] - The firm seeks recovery for investors who suffered losses due to false or misleading statements that artificially inflated stock prices [4]